Patents by Inventor Jeff S. Miller

Jeff S. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic Methods Involving Modulating Inflammasome Activation of Myeloid-Derived Suppressor Cells
    Publication number: 20210128612
    Abstract: In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.
    Type: Application
    Filed: December 11, 2020
    Publication date: May 6, 2021
    Inventors: Bruce R. Blazar, Brent Koehn, Peter J. Murray, Jenny P. Y. Ting, Robert Zeiser, Jeff S. Miller
  • Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells
    Patent number: 10894061
    Abstract: In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: January 19, 2021
    Assignees: Regents of the University of Minnesota, The University of North Carolina at Chapel Hill, St. Jude Children's Research Hospital, Inc.
    Inventors: Bruce R. Blazar, Brent Koehn, Peter J. Murray, Jenny P. Y. Ting, Robert Zeiser, Jeff S. Miller
  • THERAPEUTIC METHODS INVOLVING MODULATING INFLAMMASOME ACTIVATION OF MYELOID-DERIVED SUPPRESSOR CELLS
    Publication number: 20180214483
    Abstract: In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.
    Type: Application
    Filed: August 5, 2016
    Publication date: August 2, 2018
    Inventors: Bruce R. Blazar, Brent Koehn, Peter J. Murray, Jenny P.Y. Ting, Robert Zeiser, Jeff S. Miller